Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,472.00
Bid: 12,492.00
Ask: 12,496.00
Change: 74.00 (0.60%)
Spread: 4.00 (0.032%)
Open: 12,432.00
High: 12,526.00
Low: 12,318.00
Prev. Close: 12,398.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-India celebrates 1 billion COVID-19 vaccine doses with song and dance

Thu, 21st Oct 2021 06:21

* India reaches milestone after slow start in mid-January

* Huge disparity between partly and fully vaccinated people

* WHO, UNICEF congratulate India, urge it to resume COVAX
supplies
(Adds graphics, UNICEF comment)

By Krishna N. Das

NEW DELHI, Oct 21 (Reuters) - India celebrated the milestone
of administering 1 billion COVID-19 vaccine doses on Thursday,
with the government promoting the achievement in song and video
even as a recent drop in inoculations worries healthcare
providers.

After a slow beginning in the middle of January, India's
immunisation campaign has covered three-quarters of its 944
million adults with at least one dose but only 31% with two. The
government wants all adults to get vaccinated this year.

"India scripts history," Prime Minister Narendra Modi said
on Twitter. "We are witnessing the triumph of Indian science,
enterprise and collective spirit of (1.3 billion) Indians."

Modi marked the occasion by interacting with healthcare
workers and a security guard at a government hospital in New
Delhi. The health ministry announced musical and other
programmes across the country, and special illuminations of
national monuments including a colonial-era jail.

Nearly 90% of the vaccines administered in India have come
from the Serum Institute of India (SII), which produces a
licensed version of the AstraZeneca drug. SII has more
than tripled its capacity since April and can now produce 220
million vaccine doses a month.

SII has also slowly resumed exports for the first time since
April, when the government stopped all overseas sales to meet
domestic demand as infections rose dramatically.

The World Health Organization (WHO), which relies heavily on
India for supplies to its global vaccine-sharing platform COVAX,
congratulated the country for reaching the landmark.

"India's progress must be viewed in the context of the
country's commendable commitment and efforts to ensure that
these life-saving vaccines are accessible globally," said Poonam
Khetrapal Singh, regional director WHO South-East Asia.

COVAX partner UNICEF also congratulated India and said it
looked forward to "hearing details about the expected timeline
and volumes of supplies to be made" to the global facility.

Reuters has reported that India has delayed supplies of the
AstraZeneca vaccine to COVAX https://www.reuters.com/world/india/india-delays-covid-19-vaccine-supplies-who-backed-covax-sources-say-2021-10-19.
New Delhi has been annoyed by the WHO's repeated delay in
adding India's own Covaxin shot to the world body's
emergency-use listing https://twitter.com/DrTedros/status/1450574012027920402,
something both parties discussed this week as well as exports.

India has so far reported 34.1 million COVID-19 cases and
more than 452,000 deaths, most during a second wave of
infections of the Delta variant between April and May.

A "sizeable number https://www.reuters.com/article/health-coronavirus-india/many-indians-skipping-second-covid-shot-despite-record-vaccine-stocks-idUSL4N2RF2G3
" of people in India have not taken their second dose by the due
date despite adequate supplies, the health ministry said on
Tuesday, as new infections fell to their lowest since early
March.

Daily shots have averaged 5 million this month, a fifth of
September's peak, though states are sitting on record stocks of
more than 100 million as domestic output of the AstraZeneca
vaccine soars.

Despite the current low number of infections, ministry
officials have been urging people to get vaccinated fast,
especially as the ongoing festival season means family
gatherings and mass shopping, raising the risk of a new wave of
infections.

(Reporting by Krishna N. Das; Editing by Lincoln Feast and
Giles Elgood)

More News
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more
25 Apr 2024 09:18

TOP NEWS: AstraZeneca upbeat as cancer drugs underpin sales growth

(Alliance News) - AstraZeneca PLC on Thursday hailed the potential of its drugs pipeline as it delivered impressive growth in sales and profit in the first quarter.

Read more
25 Apr 2024 09:12

LONDON MARKET OPEN: Anglo American jumps on takeover bid from BHP

(Alliance News) - Stock prices in London opened mixed on Thursday, as investors cautiously eye data on the health of the US economy.

Read more
25 Apr 2024 08:38

AstraZeneca blows past analysts' estimates for Q1

(Sharecast News) - AstraZeneca posted better-than-expected revenues and profit for the first quarter of 2024 with both the company and analysts highlighting its drug pipeline.

Read more
25 Apr 2024 07:56

REPEAT: Miner Anglo American reviews takeover bid from rival BHP

(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.

Read more
25 Apr 2024 07:52

Sanofi profit slips on generic competition and currency effects

April 25 (Reuters) - Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday.

Read more
25 Apr 2024 07:43

LONDON BRIEFING: Miner Anglo American eyes rival BHP takeover

(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.

Read more
25 Apr 2024 06:30

Sanofi Q1 profit slips on generic competition, forex effects

April 25 (Reuters) - Sanofi's said on Thursday first-quarter operating income declined 14.7% as unfavourable currency effects and cheap competition to multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.